's () (OTCQX:ANPCY) Andrew Newland speaks to Proactive to update on progress since the COVID-19 lockdown began.
He says a key focus during the period has been on finalising the significant amount of written documentation and analysis for the firm’s imminent submission to the US Food & Drug Administration.
Newland also discusses how he believes its ground-breaking liquid biopsy system could have a role to play helping guide trials in cancer immunotherapies.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...
FOR OUR FULL DISCLAIMER CLICK HERE